Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avidan U Neumann

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
Nanomaterials (Basel, Switzerland)|September 30, 2017
Pro-Inflammatory versus Immunomodulatory Effects of Silver Nanoparticles in the Lung: The Critical Role of Dose, Size and Surface ModificationFrancesca Alessandrini, Antje Vennemann, Silvia Gschwendtner, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 21, 2012
Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis CStéphanie Pascarella, Sophie Clément, Michael T Dill, et al.
Antimicrobial Agents and Chemotherapy|November 7, 2007
Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivityHelen Cooksley, Shilpa Chokshi, Yafit Maayan, et al.
World Journal of Gastroenterology|December 5, 2006
Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapyJose-Eymard Medeiros-Filho, Isabel-Maria-Vicente-Guedes de Carvalho Mello, Joao-Renato-Rebello Pinho, et al.
Hepatology (Baltimore, Md.)|December 26, 2006
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6Esther Lukasiewicz, Kristoffer Hellstrand, Johan Westin, et al.
Hepatology (Baltimore, Md.)|February 27, 2010
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis CGalia Askarieh, Asa Alsiö, Paolo Pugnale, et al.
The World Allergy Organization Journal|March 18, 2020
Physical and immunological barrier of human primary nasal epithelial cells from non-allergic and allergic donorsCarolin Bergougnan, Daniela C Dittlein, Elke Hümmer, et al.
Frontiers in Immunology|April 26, 2019
The Role of Pre-existing Cross-Reactive Central Memory CD4 T-Cells in Vaccination With Previously Unseen Influenza StrainsMikalai Nienen, Ulrik Stervbo, Felix Mölder, et al.
Kidney International|March 15, 2013
The genetic predisposition of natural killer cell to BK virus-associated nephropathy in renal transplant patientsHanna Trydzenskaya, Karsten Juerchott, Nils Lachmann, et al.
AIDS (London, England)|November 10, 2009
Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamicsLynn Rozenberg, Bart L Haagmans, Avidan U Neumann, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Nanomaterials (Basel, Switzerland)|September 30, 2017
Pro-Inflammatory versus Immunomodulatory Effects of Silver Nanoparticles in the Lung: The Critical Role of Dose, Size and Surface ModificationFrancesca Alessandrini, Antje Vennemann, Silvia Gschwendtner, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 21, 2012
Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis CStéphanie Pascarella, Sophie Clément, Michael T Dill, et al.
Antimicrobial Agents and Chemotherapy|November 7, 2007
Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivityHelen Cooksley, Shilpa Chokshi, Yafit Maayan, et al.
World Journal of Gastroenterology|December 5, 2006
Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapyJose-Eymard Medeiros-Filho, Isabel-Maria-Vicente-Guedes de Carvalho Mello, Joao-Renato-Rebello Pinho, et al.
Hepatology (Baltimore, Md.)|December 26, 2006
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6Esther Lukasiewicz, Kristoffer Hellstrand, Johan Westin, et al.
Hepatology (Baltimore, Md.)|February 27, 2010
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis CGalia Askarieh, Asa Alsiö, Paolo Pugnale, et al.
The World Allergy Organization Journal|March 18, 2020
Physical and immunological barrier of human primary nasal epithelial cells from non-allergic and allergic donorsCarolin Bergougnan, Daniela C Dittlein, Elke Hümmer, et al.
Frontiers in Immunology|April 26, 2019
The Role of Pre-existing Cross-Reactive Central Memory CD4 T-Cells in Vaccination With Previously Unseen Influenza StrainsMikalai Nienen, Ulrik Stervbo, Felix Mölder, et al.
Kidney International|March 15, 2013
The genetic predisposition of natural killer cell to BK virus-associated nephropathy in renal transplant patientsHanna Trydzenskaya, Karsten Juerchott, Nils Lachmann, et al.
AIDS (London, England)|November 10, 2009
Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamicsLynn Rozenberg, Bart L Haagmans, Avidan U Neumann, et al.
Pageof 9